European Union Horizon 2020 research & innovation ProgrammE

SME Instruments Phase 2 Development Programme

In May 2018, ATXA Therapeutics Limited secured €2.5 million funding under the EU Horizon 2020 SME Instrument programme. ATXA won this funding from a highly competitive field of 1280 applications, with a total of 64 grants awarded, and was ranked within the top 1% of all applicants. Securing the Horizon 2020 SME Instrument award will be a key accelerant in bringing ATXA’s NTP42 closer to the market by advancing the drug into clinical development.

This project received funding from the European Union Horizon 2020 research and innovation programme under Grant Agreement No 822258.

New Hope for the PAH Patient: A Novel Therapeutic for Pulmonary Arterial Hypertension (PAH) - PAH-HOPE


PAH is a debilitating lung & heart disease with an urgent need for new medicines targeting different pathways than current drugs. These drugs do not effectively treat the disease, they carry serious side-effects, are poorly tolerated and only extend life-expectancy from 2.8 years (untreated) to 3.6 years (treated).

ATXA has developed novel therapeutic drugs to treat PAH. ATXA’s drug target is the human Thromboxane Receptor, a pathway involved in all the clinical features of PAH. Based on evaluations in 2 independent animal models of PAH, ATXA’s lead NTP42 is predicted to be a truly disruptive disease-modifying drug, treating all aspects of PAH and greatly extending life expectancy. ATXA has completed the preclinical phase of its drug development program and has secured orphan designation from the EMA and FDA regulatory agencies for NTP42 for PAH treatment.

The objective of PAH-HOPE is to advance ATXA’s drug NTP42 into clinical development, starting from scaled up drug manufacture through to securing regulatory clinical trial authorization (CTA). Securement of CTA will position ATXA to advance NTP42 to Phase I-III clinical trials through to marketing authorization and product launch in 2025. ATXA’s NTP42 fits with the current focus on value-based healthcare delivery, resulting in improved healthcare outcomes that matter to patients, physicians, payors but at lower cost of delivery.

Commenced October 2018, the PAH-HOPE project comprises four major Work Packages (WPs), alongside ancillary management, governance and communication programmes.

About SME Instrument

The SME Instrument is part of the European Innovation Council (EIC) pilot that supports top class innovators, entrepreneurs and small companies with funding opportunities and acceleration services. The main focus of the SME Instrument is on market-creating innovations that shape new markets and generate jobs, growth and higher standards of living.


Please click here to learn more about funding opportunities through the SME Instrument.

For further information and updates, follow our dedicated PAH-HOPE Twitter feed:

  • Twitter

© 2021 by ATXA Therapeutics Limited.

Dublin, Ireland

Home  |  About Us  |  News  |  Contact Us

Follow us on:

  • LinkedIn Social Icon
  • Facebook Social Icon
  • Twitter Social Icon